Sharechat Logo

F&P Healthcare files patent complaint against rival ResMed; earnings outlook unchanged

Tuesday 11th September 2018

Text too small?

Fisher & Paykel Healthcare has filed a complaint against its rival ResMed, alleging some of ResMed's masks used to treat obstructive sleep apnea infringe its patents.

Auckland-based F&P Healthcare said it has filed a complaint with the US International Trade Commission, alleging the AirFit P10 for Her masks and AirFit P10 for AirMini masks infringe five of its patents and seeking a permanent exclusion order and cease and desist order to prevent the sale and importation of the AirFit P10 range of masks in the US.

“Over the past 20 years, Fisher & Paykel Healthcare has built a significant portfolio of more than 2,000 issued and pending patents," F&P Healthcare managing director Lewis Gradon said in a statement. "We have developed unique mask technology that has provided improved care and outcomes for patients with OSA and we take infringement of our intellectual property rights very seriously.”

F&P Healthcare's action comes hot on the heels of a complaint to the commission from ResMed earlier this month, where the US company sought to ban the importation and sale of F&P Healthcare's Simplus full face mask, Eson nasal mask and Eson 2 nasal mask in the US, and separately lodged a new suit in the US district court accusing the Kiwi firm of patent infringement and seeking damages plus an injunction against future sales of the masks. 

The rival companies have been locked in litigation since 2016 spanning the US, UK, Europe, New Zealand and Australia.

F&P Healthcare spent $15.6 million on litigation in the year ended March 31, 2018, down from $20.7 million a year earlier. F&P Healthcare said today its earnings guidance for the 2019 financial year remains unchanged as its latest update on Sept. 3  allowed for legal costs of the latest action. That guidance said the patent dispute would cut annual earnings by as much as $10 million to a range of $205 million to $210 million in the year ending March 31, 2019, from a previous forecast of $215 million.

F&P Healthcare shares slipped 0.3 percent to $14.75, having gained 15 percent over the past year. 

(BusinessDesk)

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Take care to avoid "unnecessary" cost in electrifying economy - Vivid
Is this the calm before a storm of credit card thrashing?
Shrinking meat and dairy product manufacturing weighs on growth outlook
Jon Macdonald to stay on as Trade Me boss through takeover tussle
Shareholders’ Association wants Finzsoft to come clean
A2 rings in more executive changes under new CEO Hrdlicka
NZ dollar dips as China-US trade tensions cast pall over global markets
No end in sight to global market turmoil
MARKET CLOSE: NZ shares rally on speculation of flat US rate track; Spark gains
Fed's wait-and-see signal keeps NZ dollar steady for the week

IRG See IRG research reports